A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial

ConditionHuman Papillomavirus-Related Carcinoma

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age9+

SponsorEmory University

About this trial

This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, which estimated that increasing HPV vaccination rates can prevent 400,000 HPV-related cancers in the next 5-10 years. The goal is for HPV vaccinations to be completed by the age of 13. It has been estimated that only about 16% of adolescents were fully up to date with HPV vaccines by age 13. Strong and consistent provider recommendations have been shown to play an important role in the uptake of vaccines. In addition, education and information received by parents may improve the strength of recommendations by providers. The TweenVax intervention includes practice, provider, parent and patient level education to teach best practices, help with vaccine messaging, and give correct and easy to understand information to parents. Providing practice, provider and parent level access to TweenVax may be more effective than current vaccine promotion practices in improving HPV vaccination rates in adolescents.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

PRACTICE-LEVEL: Must be community based primary care providers (pediatrics or family practice)

PRACTICE-LEVEL: Are willing to be part of the study

PRACTICE-LEVEL: Have sufficient patient population to support 51 adolescents aged 9-12 years over approximately a 9-month period

PRACTICE-LEVEL: Utilize an electronic medical records system and/or report to the state Immunization Information System (IIS)

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

Best Practice
Other intervention
Offer standard of care adolescent vaccination promotion practices
Educational Intervention
Other intervention
Receive vaccination information
Health Promotion and Education
Other intervention
Receive all TweenVax components and trainings for the practice, providers and staff, parents and adolescents
Health Promotion and Education
Other intervention
Receive components and trainings for the practice and provider levels
Internet-Based Intervention
Other intervention
Receive access to TweenVax application

Treatment groups

1,836 Participants

are divided into 3 treatment groups

Group A: Arm I (TweenVax, practice, provider, parent, patient level)Experimental treatment 3 interventions

Group B: Arm II (practice and provider)Experimental treatment 1 intervention

Group C: Arm III (control)Active comparator 1 intervention

Trial outcomes

Primary outcomes

Initiation and completion of human papillomavirus (HPV) vaccine by 13 years of age

Will do a direct comparison of rates in the intervention groups relative to the control group. However, if there is an imbalance in covariates between the arms, will then use multivariable regression, accounting for clinic-level clustering and key covariates. If needed, the initial regression model will be a log-binomial regression, to directly estimate relative risk; however, the final modeling choice will be dependent on the actual distribution of the data which may necessitate an alternative modeling method. Each intervention arm will be compared to the control arm independently, and analysis will be conducted separately for HPV vaccine series initiation and completion. Will model vaccination rates with associated 95% confidence intervals, and comparisons between intervention arms will be conducted by comparing confidence intervals.

Time frame

Up to 1 year follow-up

Secondary outcomes

Rate of missed opportunities for vaccination

Will assess the total number of healthcare encounters, classifying them as whether the adolescent was eligible for HPV vaccine at the time of the visit. Eligible visits with no vaccine administered, when a vaccine could have been administered based on eligibility, will be considered a missed opportunity. Will compare the mean number of missed opportunities per arm using analysis of variance, and the proportion of adolescents with at least one missed opportunity per arm using Fisher's exact test.

Time frame

Up to 1 year follow-up

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Emory University

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov

Apply now